Synerzys Novaceuticals Private Limited

U24100TG2015PTC098988ActivePrivateUnlisted
Last updated: 2026-06-07
30
Compliance Health · F
3 / 9 signals passed

Synerzys Novaceuticals Private Limited is a Private Indian company incorporated in 2015 and based in Telangana, India. Synerzys Novaceuticals Private Limited operates in Pharmaceuticals & Chemicals (NIC 24100) with authorized capital of —. RegisterKaro's Compliance Health Score for the company is 30/100 (grade F), reflecting a weak compliance posture.

Risk FlagsFinancials not yet extracted · awaiting AOC-4 XBRLDirectors not yet extracted · awaiting MGT-7Health F · 30/100
Revenue (latest FY)
Awaiting extraction
PAT (latest FY)
Awaiting extraction
Open Charges
0
No encumbrances
Active Directors
0
No resignations
Paid-up Capital
Filings on Record
0
All current
Incorporated
2015
11 years old
State
Telangana
Sector
Pharmaceuticals & Chemicals
NIC 24100
Class
Private
Sub-category
Authorized Capital
Paid-up Capital
Members
Last AGM
Last Balance Sheet
Latest Filing
Registered Email
Registered Office
SYNERZYS NOVACEUTICALS PRIVATE LIMITEDTRACXN · PUBLIC DATA
Brand SYNERZYS NOVACEUTICALS PRIVATE LIMITED · Legal entity Synerzys Novaceuticals Private Limited
Total Funding
Latest Round
Revenue
Valuation
Funding Rounds
Employees
Stage
HQ
Founded
2015
Source: Tracxn (public profile) · joined to MCA on CIN U24100TG2015PTC098988

Quick facts

Identity · Activity · Auditor · Contact
Registered office
NIC code
24100
Statutory auditor
Awaiting ADT-1 / AOC-4 extraction
Registered email
Section
Pharmaceuticals & Chemicals
ROC
Class · sub-category
Private
Incorporation · Last AGM
·

Directors

From MGT-7 annual returnLocked
PN
Priya Nair
Additional Director
6.6y · Pune · DIN 4493743
KB
Kunal Bhatia
Managing Director
7.6y · Pune · DIN 6006534
Get the full board of directors

Directors, DINs & appointment history for Synerzys Novaceuticals Private Limited.

₹499₹169(excl. taxes)
Buy Financial & Company Filings
What you'll get
  • Incorporation Documents
  • Change in Directors & Designated Partner
  • Board Resolutions
  • Financial Statements & Annual Filings
  • Charge Documents (Summary)

MCA Filings

AOC-4 · MGT-7 historyLocked
FormFYFiledDueDelayStatus
AOC-4FY2024-2530 Oct 202430 Oct 20240dfiled
MGT-7FY2024-2526 Nov 202429 Nov 20240dfiled
AOC-4FY2023-2430 Oct 202330 Oct 20230dfiled
MGT-7FY2023-2423 Nov 202329 Nov 20230dfiled
AOC-4FY2022-2330 Oct 202230 Oct 20220dfiled
MGT-7FY2022-2327 Nov 202229 Nov 20220dfiled
Get financial statements & other filing documents

Full MCA filing history for Synerzys Novaceuticals Private Limited.

₹499₹169(excl. taxes)
Buy Financial & Company Filings
What you'll get
  • Incorporation Documents
  • Change in Directors & Designated Partner
  • Board Resolutions
  • Financial Statements & Annual Filings
  • Charge Documents (Summary)

Charges

Registered charges & encumbrancesLocked
Charge IDHolderAmountCreatedStatus
153868624HDFC Bank Ltd(Bank)₹6.76 Cr12 Mar 2023Satisfied
597978019Axis Bank Ltd(Bank)₹3.88 Cr19 Sep 2023Satisfied
985489113HDFC Bank Ltd(Bank)₹19.18 Cr27 Jan 2020Satisfied
120220124Axis Bank Ltd(Bank)₹10.49 Cr04 Jul 2023Satisfied
380065571HDFC Bank Ltd(Bank)₹17.78 Cr04 Jul 2019Satisfied
725536543HDFC Bank Ltd(Bank)₹18.44 Cr27 Jan 2023Satisfied
See registered charges & lenders

Charge IDs, lenders & amounts for Synerzys Novaceuticals Private Limited.

₹499₹169(excl. taxes)
Buy Financial & Company Filings
What you'll get
  • Incorporation Documents
  • Change in Directors & Designated Partner
  • Board Resolutions
  • Financial Statements & Annual Filings
  • Charge Documents (Summary)

Financial Performance

Revenue · PAT · Net worth by FYLocked
FYRevenuePATNet WorthTotal AssetsEmployees
FY2024-25₹18.57 Cr₹79.17 L₹20.05 Cr₹29.19 Cr330
FY2023-24₹16.28 Cr₹96.91 L₹13.24 Cr₹20.27 Cr278
FY2022-23₹14.74 Cr₹1.15 Cr₹11.92 Cr₹19.30 Cr181
FY2021-22₹15.27 Cr₹67.21 L₹14.03 Cr₹23.18 Cr17
Gain deeper financial insights of this entity

Audited financials & ratios for Synerzys Novaceuticals Private Limited.

₹999₹249(excl. taxes)
Buy Financial Report
What you'll get
  • Financial Summary & Charts
  • Income Statement, Balance Sheet, Cashflow
  • Profitability, Liquidity & Growth Ratios
  • Audited Financial Statement (AOC-4)

Detailed Financials

Income statement + balance sheetLocked
Line itemFY2024-25FY2023-24FY2022-23FY2021-22
Income statement
Revenue from operations₹18.57 Cr₹16.28 Cr₹14.74 Cr₹15.27 Cr
Other income₹32.52 L₹31.82 L₹25.44 L₹59.05 L
Total income₹18.89 Cr₹16.59 Cr₹14.99 Cr₹15.86 Cr
Total expenses₹17.88 Cr₹15.35 Cr₹13.52 Cr₹15.00 Cr
Profit before tax₹1.03 Cr₹1.26 Cr₹1.49 Cr₹87.37 L
Profit / (Loss) after tax₹79.17 L₹96.91 L₹1.15 Cr₹67.21 L
Balance sheet
Equity / Net worth₹20.05 Cr₹13.24 Cr₹11.92 Cr₹14.03 Cr
Borrowings₹3.34 Cr₹3.86 Cr₹2.88 Cr₹2.14 Cr
Current liabilities₹3.40 Cr₹3.98 Cr₹2.33 Cr₹4.24 Cr
Total liabilities₹9.14 Cr₹7.03 Cr₹7.38 Cr₹9.15 Cr
Current assets₹15.59 Cr₹10.07 Cr₹11.07 Cr₹12.63 Cr
Cash & equivalents₹3.71 Cr₹2.58 Cr₹3.42 Cr₹2.08 Cr
Total assets₹29.19 Cr₹20.27 Cr₹19.30 Cr₹23.18 Cr
Employees33027818117
Gain deeper financial insights of this entity

Audited financials & ratios for Synerzys Novaceuticals Private Limited.

₹999₹249(excl. taxes)
Buy Financial Report
What you'll get
  • Financial Summary & Charts
  • Income Statement, Balance Sheet, Cashflow
  • Profitability, Liquidity & Growth Ratios
  • Audited Financial Statement (AOC-4)

Compounded Annual Growth Rate

Derived from multi-FY filingsLocked
MetricLatest value1Y CAGR3Y CAGR5Y CAGR
Revenue₹18.57 Cr+7.6%+14.1%-0.0%
Profit after Tax₹79.17 L+1.1%+2.4%+19.3%
Net Worth₹20.05 Cr+2.6%+12.7%+4.0%
Employees330+6.3%+7.2%+21.6%
Gain deeper financial insights of this entity

Audited financials & ratios for Synerzys Novaceuticals Private Limited.

₹999₹249(excl. taxes)
Buy Financial Report
What you'll get
  • Financial Summary & Charts
  • Income Statement, Balance Sheet, Cashflow
  • Profitability, Liquidity & Growth Ratios
  • Audited Financial Statement (AOC-4)

Financial Ratios

Profitability · leverage · efficiencyLocked
FYRevenuePATPAT marginRev growthROEROAD/ERev/emp
FY2024-25₹18.57 Cr₹79.17 L+4.26%+19.22%+3.95%+2.71%0.17₹5.63 L
FY2023-24₹16.28 Cr₹96.91 L+5.95%+38.31%+7.32%+4.78%0.29₹5.85 L
FY2022-23₹14.74 Cr₹1.15 Cr+7.78%+17.85%+9.62%+5.94%0.24₹8.14 L
FY2021-22₹15.27 Cr₹67.21 L+4.40%+28.62%+4.79%+2.90%0.15₹89.81 L
Gain deeper financial insights of this entity

Audited financials & ratios for Synerzys Novaceuticals Private Limited.

₹999₹249(excl. taxes)
Buy Financial Report
What you'll get
  • Financial Summary & Charts
  • Income Statement, Balance Sheet, Cashflow
  • Profitability, Liquidity & Growth Ratios
  • Audited Financial Statement (AOC-4)

Cap Table & Shareholding

Promoter · institutional · publicLocked
CategoryShareholdersShares held%
Promoters41,88,74,68559.93%
Institutional Investors149,62,41015.76%
Public & Others3676,58,88624.32%
See the full shareholding pattern

Promoter, institutional & public holding for Synerzys Novaceuticals Private Limited.

₹499₹169(excl. taxes)
Buy Financial & Company Filings
What you'll get
  • Incorporation Documents
  • Change in Directors & Designated Partner
  • Board Resolutions
  • Financial Statements & Annual Filings
  • Charge Documents (Summary)

Peer Benchmark

338 peersSame sector + state + ±5y vintage
MetricThis companyCohort medianCohort P75Quartile
Revenue (latest FY)
PAT (latest FY)
Employees
Paid-up capital
Compliance Health
63
96
96
Bottom quartile · P1

Top 10 in Pharmaceuticals & Chemicals

by healthView all ›
01
Paid-up
Revenue
A · 96
02
Paid-up
Revenue
A · 96
03
Paid-up
Revenue
A · 96
04
Paid-up
Revenue
A · 96
05
S B Organics Ltd
Telangana · Inc 1988
Paid-up
Revenue
A · 96
06
Ecmas Resins PVT Ltd
Telangana · Inc 1987
Paid-up
Revenue
A · 96
07
Srinivasa Cystine Private Ltd
Telangana · Inc 1983
Paid-up
Revenue
A · 96
08
Paid-up
Revenue
A · 96
09
Paid-up
Revenue
A · 96
10
Paid-up
Revenue
A · 96

External data sources

7 plannedWhat lands here as ingestion comes online

GSTIN Registrations

Planned
GST portal

Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.

MSME Payment Delays

Planned
MSME-1 form

Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.

Related Party Transactions

Planned
AOC-4 schedule

Counterparty, nature, transaction value. Inter-company loans, sales, royalty.

Credit Ratings

Planned
CRISIL / ICRA / CARE feeds

Long-term + short-term ratings, with rationale on rating actions.

Trademarks

Planned
IP India Trademark Registry

Applied, registered, opposed. Class numbers + status.

Patents

Planned
IP India Patent Registry

Applications and grants. Inventor names + filing dates.

Legal Cases

Planned
eCourts + Indian Kanoon

Ongoing + past litigations the entity is party to.

Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.

FAQs about Synerzys Novaceuticals Private Limited

When was Synerzys Novaceuticals Private Limited incorporated?
Synerzys Novaceuticals Private Limited was incorporated in 2015. Its CIN is U24100TG2015PTC098988 and it is registered with the relevant Registrar of Companies.
Where is Synerzys Novaceuticals Private Limited located?
Synerzys Novaceuticals Private Limited is headquartered in Telangana.
What sector does Synerzys Novaceuticals Private Limited operate in?
Synerzys Novaceuticals Private Limited operates in the Pharmaceuticals & Chemicals sector (NIC code 24100), classified as Indian Non-Govt Company.
Who are the directors of Synerzys Novaceuticals Private Limited?
Director details for Synerzys Novaceuticals Private Limited have not yet been extracted from MGT-7 filings.
What is the paid-up capital of Synerzys Novaceuticals Private Limited?
Synerzys Novaceuticals Private Limited has authorized capital of — and paid-up capital of —.
Does Synerzys Novaceuticals Private Limited have any open charges?
Synerzys Novaceuticals Private Limited has no open MCA-registered charges on record.
What is Synerzys Novaceuticals Private Limited's Compliance Health Score?
RegisterKaro's Compliance Health Score for Synerzys Novaceuticals Private Limited is 30/100 (grade F), based on 9 weighted signals across MCA filings, charges, directors, capital, and overall status. 3 of 9 signals passed.